BIONET Therapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	196.63	154.48	81.32	5.37	-
Revenue Growth	86.07%	89.96%	1414.60%	-	-
Cost of Revenue	97.53	92.83	79.3	3.57	-
Gross Profit	99.1	61.65	2.02	1.8	-
Selling, General & Admin	138.43	115.89	54.14	6.31	0.67
Research & Development	62.33	62.2	47.24	34.75	11.86
Operating Expenses	200.77	178.1	101.38	41.06	12.53
Operating Income	-101.67	-116.45	-99.36	-39.26	-12.53
Interest Expense	-0.37	-0.08	-	-	-
Interest & Investment Income	17.07	18.03	11.82	1.89	0.02
Other Non Operating Income (Expenses)	1.89	1.07	1.29	0.03	-
Pretax Income	-84.09	-97.43	-86.26	-37.34	-12.52
Net Income	-84.09	-97.43	-86.26	-37.34	-12.52
Net Income to Common	-84.09	-97.43	-86.26	-37.34	-12.52
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	70	70	57	15	1
Shares Outstanding (Diluted)	70	70	57	15	1
Shares Change	3.39%	21.88%	280.50%	1278.45%	-
EPS (Basic)	-1.20	-1.39	-1.50	-2.47	-11.43
EPS (Diluted)	-1.20	-1.39	-1.50	-2.47	-11.43
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-90.79	-138.68	-170.95	-46.26	-3.47
Free Cash Flow Per Share	-1.29	-1.98	-2.98	-3.06	-3.17
Gross Margin	50.40%	39.91%	2.48%	33.49%	-
Operating Margin	-51.71%	-75.38%	-122.19%	-731.20%	-
Profit Margin	-42.77%	-63.07%	-106.07%	-695.44%	-
Free Cash Flow Margin	-46.17%	-89.77%	-210.22%	-861.52%	-
EBITDA	-81.75	-105.43	-96.12	-38.68	-
EBITDA Margin	-41.57%	-68.25%	-118.21%	-	-
D&A For EBITDA	19.93	11.02	3.24	0.58	-
EBIT	-101.67	-116.45	-99.36	-39.26	-12.53
EBIT Margin	-51.71%	-75.38%	-122.19%	-	-